Recombinant Mouse LOXL2 Protein (His Tag)
Beta LifeScience
SKU/CAT #: BLPSN-3224
Recombinant Mouse LOXL2 Protein (His Tag)
Beta LifeScience
SKU/CAT #: BLPSN-3224
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Tag | His |
Host Species | Mouse |
Accession | NP_201582.2 |
Synonym | 1110004B06Rik, 4930526G11Rik, 9430067E15Rik |
Background | Lysyl oxidase homolog 2, also known as Lysyl oxidase-like protein 2, Lysyl oxidase-related protein 2, Lysyl oxidase-related protein WS9-14 and LOXL2, is a secreted protein which belongs to thelysyl oxidase family. LOXL2 contains fourSRCR domains. The lysyl oxidase family is made up of five members: lysyl oxidase (LOX) and lysyl oxidase-like 1-4 ( LOXL1, LOXL2, LOXL3, LOXL4 ). All members share conserved C-terminal catalytic domains that provide for lysyl oxidase or lysyl oxidase-like enzyme activity; and more divergent propeptide regions. LOX family enzyme activities catalyze the final enzymatic conversion required for the formation of normal biosynthetic collagen and elastin cross-links. LOXL2 is expressed by pre-hypertrophic and hypertrophic chondrocytes in vivo, and that LOXL2 expression is regulated in vitro as a function of chondrocyte differentiation. LOXL2 promotes chondrocyte differentiation by mechanisms that are likely to include roles as both a regulator and an effector of chondrocyte differentiation. LOXL2 expression could also be explored as a molecular target in the prevention of breast cancer progression. |
Description | A DNA sequence encoding the mouse Loxl2 (NP_201582.2) (Met1-Gln776) was expressed with a His tag at the C-terminus. |
Source | HEK293 |
Predicted N Terminal | Gln 26 |
AA Sequence | Met1-Gln776 |
Molecular Weight | The recombinant mouse Loxl2 consists 762 a.a. and predicts a molecular mass of 85.9 kDa. |
Purity | >(19.0+61.5)% as determined by SDS-PAGE |
Endotoxin | < 1.0 EU per μg protein as determined by the LAL method. |
Bioactivity | Measured by its ability to produce hydrogen peroxide during the oxidation of benzylamine.The specific activity is > 3pmoles/min/ug. |
Formulation | Lyophilized from sterile 20 mM MES, 150 mM NaCl, pH 6.5.. |
Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
Usage | For Research Use Only |
Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Target Details
Target Function | Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). Acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. Shows no activity against histone H3 when it is trimethylated on 'Lys-9' (H3K9me3) or 'Lys-27' (H3K27me3) or when 'Lys-4' is monomethylated (H3K4me1) or dimethylated (H3K4me2). Also mediates deamination of methylated TAF10, a member of the transcription factor IID (TFIID) complex, which induces release of TAF10 from promoters, leading to inhibition of TFIID-dependent transcription. LOXL2-mediated deamination of TAF10 results in transcriptional repression of genes required for embryonic stem cell pluripotency including POU5F1/OCT4, NANOG, KLF4 and SOX2. Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E-cadherin, probably by mediating deamination of histone H3. During EMT, involved with SNAI1 in negatively regulating pericentromeric heterochromatin transcription. SNAI1 recruits LOXL2 to pericentromeric regions to oxidize histone H3 and repress transcription which leads to release of heterochromatin component CBX5/HP1A, enabling chromatin reorganization and acquisition of mesenchymal traits. Interacts with the endoplasmic reticulum protein HSPA5 which activates the IRE1-XBP1 pathway of the unfolded protein response, leading to expression of several transcription factors involved in EMT and subsequent EMT induction. When secreted into the extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding. Acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation. |
Subcellular Location | Secreted, extracellular space, extracellular matrix, basement membrane. Nucleus. Chromosome. Endoplasmic reticulum. |
Protein Families | Lysyl oxidase family |
Database References | |
Tissue Specificity | Ubiquitous. Highest expression in skin, lung and thymus. Present in chondrocytes: mainly expressed by chondrocytes in healing fractures and in epiphyseal growth plates (at protein level). |
Gene Functions References
- although Loxl2 is expressed in both dermis and epidermis, its function appears largely confined to the epidermis. PMID: 29953488
- LOXL2 controls myofibroblast transformation and migration. PMID: 27966531
- The mRNA and protein expression levels of LOXL2 were higher in a mouse model of tubulointerstitial fibrosis compared with in control mice. PMID: 28677767
- Findings indicate a pathophysiologic role and function for lysyl oxidase-like protein LOXL2 in breast cancer metastasis. PMID: 28720577
- Insulin resistance promotes lysyl oxidase like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. PMID: 28468951
- glomerular extracellular matrix. Altogether, we demonstrate that LOXL2 is a novel component of the molecular machinery that forms cross-linked collagen IV networks, which are essential for glomerular basement membrane stability and molecular ultrafiltration function. PMID: 27770022
- LOX and LOXL2 may play an important role in the pathogenesis of AMD. Targeting LOXL2 could have a broader efficacy than targeting LOX, by reducing angiogenesis and inflammation, as well as fibrosis. PMID: 26258612
- Loss and gain of function analyses combined with in vivo studies in syngeneic breast cancer models demonstrate the participation of LOXL2 and E47 in tumor growth and their requirement for lung metastasis. PMID: 24632622
- promoted intrahepatic metastasis by increasing tissue stiffness PMID: 25048396
- Findings reveal new insight into the mechanisms of fibroblast activation, a novel function of LOXL2, and further highlight the importance of generating LOXL2-targeted therapies for the prevention of tumor progression and metastasis. PMID: 24008674
- The Snail1 transcription factor represses mouse pericentromeric transcription, acting through the H3K4 deaminase LOXL2. PMID: 24239292
- The enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation. PMID: 22157764
- This study provides the first evidence for the role of LOXL2 in regulating angiogenesis through collagen IV scaffolding. PMID: 21835952
- LOXL2 promotes chondrocyte differentiation by mechanisms that are likely to include roles as both a regulator and an effector of chondrocyte differentiation PMID: 21071451
- The efficacy and safety of LOXL2-specific monoclonal antibody represents a new therapeutic approach with broad applicability in oncologic and fibrotic diseases. PMID: 20818376
- LoxL2 is not expressed in MC3T3-E1 cells. PMID: 15652501